{"id":"https://openalex.org/W4404100326","doi":"https://doi.org/10.1183/13993003.congress-2024.pa2443","title":"Patients and caregivers\u2019 core aspirations to maximize the attractiveness of ASPIRE - a phase 2b trial to investigate the disease modifying potential of buloxibutid in IPF","display_name":"Patients and caregivers\u2019 core aspirations to maximize the attractiveness of ASPIRE - a phase 2b trial to investigate the disease modifying potential of buloxibutid in IPF","publication_year":2024,"publication_date":"2024-09-14","ids":{"openalex":"https://openalex.org/W4404100326","doi":"https://doi.org/10.1183/13993003.congress-2024.pa2443"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2024.pa2443","doi":"https://doi.org/10.1183/13993003.congress-2024.pa2443","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2024.pa2443","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Idiopathic interstitial pneumonias","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Asa Magnusson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095186","display_name":"Vicore Pharma (Sweden)","ror":"https://ror.org/00mkdy143","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210095186"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Asa Magnusson","raw_affiliation_strings":["1Vicore Pharma, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vicore Pharma, Stockholm, Sweden","institution_ids":["https://openalex.org/I4210095186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025677565","display_name":"Cecilia Ganslandt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095186","display_name":"Vicore Pharma (Sweden)","ror":"https://ror.org/00mkdy143","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210095186"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Cecilia Ganslandt","raw_affiliation_strings":["1Vicore Pharma, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vicore Pharma, Stockholm, Sweden","institution_ids":["https://openalex.org/I4210095186"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sofie Gro S\u00f8ndergaard","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sofie Gro S\u00f8ndergaard","raw_affiliation_strings":["2Quotes Health, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Quotes Health, Copenhagen, Denmark","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Louisa Channouf Jacobsen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Louisa Channouf Jacobsen","raw_affiliation_strings":["2Quotes Health, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Quotes Health, Copenhagen, Denmark","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5095944312","display_name":"Gry Willum Hagelund","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gry Willum Hagelund","raw_affiliation_strings":["3Vicore Pharma, H\u00f8rsholm, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Vicore Pharma, H\u00f8rsholm, Denmark","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5013912245","display_name":"Anne Katrine Cohrt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anne Katrine Cohrt","raw_affiliation_strings":["3Vicore Pharma, H\u00f8rsholm, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Vicore Pharma, H\u00f8rsholm, Denmark","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"PA2443","last_page":"PA2443"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10870","display_name":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","score":0.9696999788284302,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10870","display_name":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","score":0.9696999788284302,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10582","display_name":"Ethics in Clinical Research","score":0.014399999752640724,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11639","display_name":"Mental Health and Patient Involvement","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/3600","display_name":"General Health Professions"},"field":{"id":"https://openalex.org/fields/36","display_name":"Health Professions"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/idiopathic-pulmonary-fibrosis","display_name":"idiopathic pulmonary fibrosis","score":0.9950000047683716},{"id":"https://openalex.org/keywords/angiotensin-ii-type-2-receptor-agonist","display_name":"angiotensin II type 2 receptor agonist","score":0.972000002861023},{"id":"https://openalex.org/keywords/aspire-trial","display_name":"ASPIRE trial","score":0.8659999966621399},{"id":"https://openalex.org/keywords/patient-and-carer-involvement","display_name":"patient and carer involvement","score":0.6819999814033508},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.6110000014305115},{"id":"https://openalex.org/keywords/patient-feedback","display_name":"patient feedback","score":0.4230000078678131}],"concepts":[{"id":"https://openalex.org/C31173074","wikidata":"https://www.wikidata.org/wiki/Q2632514","display_name":"Attractiveness","level":2,"score":0.817795991897583},{"id":"https://openalex.org/C2164484","wikidata":"https://www.wikidata.org/wiki/Q5170150","display_name":"Core (optical fiber)","level":2,"score":0.7091820240020752},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5656380653381348},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.46939319372177124},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.4409175217151642},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.43519511818885803},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34221962094306946},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.10946640372276306},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.06632405519485474},{"id":"https://openalex.org/C76155785","wikidata":"https://www.wikidata.org/wiki/Q418","display_name":"Telecommunications","level":1,"score":0.05076858401298523},{"id":"https://openalex.org/C62520636","wikidata":"https://www.wikidata.org/wiki/Q944","display_name":"Quantum mechanics","level":1,"score":0.0},{"id":"https://openalex.org/C11171543","wikidata":"https://www.wikidata.org/wiki/Q41630","display_name":"Psychoanalysis","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2024.pa2443","doi":"https://doi.org/10.1183/13993003.congress-2024.pa2443","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2024.pa2443","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Idiopathic interstitial pneumonias","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4391375266","https://openalex.org/W2748952813","https://openalex.org/W4200508654","https://openalex.org/W4375829797","https://openalex.org/W2577455382","https://openalex.org/W2398900508","https://openalex.org/W3160315211","https://openalex.org/W4245080958","https://openalex.org/W1966920876","https://openalex.org/W2362921324"],"abstract_inverted_index":{"The":[0,200,215],"unmet":[1],"medical":[2],"need":[3],"in":[4],"idiopathic":[5],"pulmonary":[6],"fibrosis":[7],"(IPF)":[8],"remains":[9],"monumental":[10],"with":[11,68,77],"multiple":[12],"trials":[13,23],"failing":[14],"to":[15,25,193,204,220],"show":[16],"stabilization":[17],"and":[18,40,81,88,94,107,124,149,168,190,213,224],"improvement.":[19],"Additionally,":[20],"many":[21],"clinical":[22,101,128],"fail":[24],"recruit":[26],"enough":[27],"participants":[28],"or":[29],"suffer":[30],"high":[31],"dropout":[32],"rates,":[33],"increasing":[34],"the":[35,45,85,112,119,141,153,174,177,222],"hurdles":[36],"for":[37,122],"developing":[38],"new":[39],"effective":[41],"therapies.":[42],"To":[43],"increase":[44],"probability":[46],"of":[47,49,56,111,118,136,147,176,226],"success":[48],"ASPIRE,":[50],"a":[51],"52-week,":[52],"phase":[53],"2b":[54],"trial":[55,102,105,129,179,202,206,230],"buloxibutid":[57],"(C21),":[58],"an":[59,74],"oral":[60],"angiotensin":[61],"II":[62],"type":[63],"2":[64],"(AT2)":[65],"receptor":[66],"agonist":[67],"disease":[69],"modifying":[70],"potential,":[71],"Vicore":[72],"established":[73],"advisory":[75],"panel":[76,92],"six":[78],"IPF":[79,123],"patients":[80,212],"two":[82],"caregivers":[83],"from":[84,152,211],"United":[86,89],"States":[87],"Kingdom.":[90],"Semi-structured":[91],"discussions":[93],"individual":[95],"interviews":[96],"captured":[97],"feedback":[98,197,210],"on":[99],"previous":[100,127],"experiences,":[103],"ASPIRE":[104,178,201,227],"protocol":[106],"patient-facing":[108],"materials.":[109],"Each":[110],"patient":[113,166],"panellists":[114,132,143],"currently":[115],"use":[116],"one":[117],"approved":[120],"therapies":[121],"50%":[125],"had":[126],"experience.":[130],"Patient":[131,164],"were":[133,144],"61-80":[134],"years":[135,146],"age,":[137],"83%":[138],"male,":[139],"whereas":[140],"caregiver":[142],"71-80":[145],"age":[148],"female.":[150],"Insights":[151],"first":[154],"interaction":[155],"could":[156],"be":[157],"categorised":[158],"into":[159],"three":[160,216],"PF":[161],"core":[162,217],"aspirations:":[163],"first,":[165],"feedback,":[167],"promises":[169],"fulfilled.":[170],"These":[171],"insights":[172],"guided":[173],"design":[175],"by":[180],"minimizing":[181],"site":[182],"visits,":[183,186],"adding":[184],"virtual":[185],"optimizing":[187],"communication":[188],"material,":[189],"creating":[191],"means":[192],"ensure":[194],"continued":[195],"participant":[196],"during":[198],"trial.":[199],"aims":[203],"maximise":[205],"attractiveness":[207],"through":[208,228],"continuous":[209],"caregivers.":[214],"aspirations":[218],"continue":[219],"guide":[221],"conduct":[223],"reporting":[225],"empowered":[229],"participants.":[231]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2025-10-10T00:00:00"}